Combining drugs to improve cancer treatment by reversing DNA changes
Official title: Epigenetic Synergy Between DNMT and EZH1/2 Inhibitors for Therapy in Solid Tumors
Funded at Coriell Institute for Medical Research · NIH-10886785 · Data updated 2026-11-12
This study is looking at a new way to treat solid tumors by using special drugs that change how DNA works in cancer cells, which might make other treatments, like immunotherapy, work better for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Coriell Institute for Medical Research NIH-funded |
| Lab location | 1 site (Camden, United States) |
| Project start | August 16, 2021 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $460,981 |
| NIH project number | 5P50CA254897-04 |
| Project ID | NIH-10886785 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with solid tumors who have not responded adequately to current treatments.
✕Less likely to help
Patients with non-solid tumors or those who have not been diagnosed with cancer may not benefit from this research.
What this research studies
This research investigates the use of DNA methyltransferase inhibitors (DNMTi) alongside EZH1/2 inhibitors to enhance cancer treatment, particularly for solid tumors. The approach focuses on reversing abnormal DNA methylation in cancer cells, which can improve the effectiveness of immunotherapy. By blocking certain repressive activities that contribute to treatment resistance, the study aims to uncover new mechanisms that could lead to better patient outcomes. Patients may benefit from a combination therapy that targets both DNA methylation and immune response pathways.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that enhance the immune system's ability to fight tumors.
How similar studies have gone: Previous research has shown promising results with similar combinations of epigenetic therapies, indicating potential for success in this novel approach.
Where this research is happening
-
Coriell Institute for Medical Research
Camden, United States Active
Researchers
- Principal investigator: Rothbart, Scott — Coriell Institute for Medical Research
- Study coordinator: Rothbart, Scott
Related research
Other NIH-funded projects on the same topics.
-
Pediatric Preclinical In Vivo Testing Center for Pediatric Sarcoma and Other Solid Tumors
A program uses mouse tumor models to identify promising drug candidates for children with sarcoma and other solid tumors.
-
Engineered CAR T immune cells targeting GPC3 for children's solid tumors
Engineered CAR T immune cells that produce IL-15 and IL-21 to better find and fight GPC3-positive solid tumors in children.
-
Boosting CAR T cell power in solid tumors by turning on transcription factors
A new research project tests whether turning on specific human transcription factors can make CAR T cells work better against solid tumors.
-
Engineering CD19 mimotopes to boost and broaden CD19-CAR T cell therapy
A patient-focused look at improving existing CD19-CAR T cell therapy so more people with blood cancers might benefit.
-
Radio-triggered CAR-T cells to better control solid tumors
A new approach uses radiation to turn on and guide CAR-T cells to fight solid tumors more effectively, potentially improving local and distant tumor control for patients with cancer.
-
Understanding how cell behavior changes drive breast cancer in 3D cultures
Researchers are studying how breast cells transition toward cancer using advanced 3D cultures and patient-derived samples to uncover important cell-state changes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.